• Skip the Organizational structure panel
• Organizational structure

  On selecting a constituent part of MU the "List of projects" page will be displayed with information relevant to the selected constituent part. The "List of projects" page is not available for non-activated items.

  Masaryk University

  • Faculties
  • Law
  • Medicine
  • Science
  • Arts
  • Education
  • Economics
  • Informatics
  • Social Studies
  • Sports Studies

  • Rector`s Office
  • Rectorate
  • Institutes
  • Computer Science
  • CEITEC MU
  • Specialized Units
  • Hostels & Canteens
  • University Press
  • UCB Management

  • Other Units
  • Archive
  • Language Centre
  • International Studies
  • Disabled Students
  • Technology Transfer Office
  • Biostatistics
  • Mendel Museum
  • CERIT
  • CEITEC Central Management
  • Telč Centre

   

Project details

From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

Project Identification:	MSM0021622434
Project Period:	1/2007 - 12/2013
Investor:	Ministry of Education, Youth and Sports of the CR
Programme / Project Type:	Research Intents -
MU Faculty/Unit:	Faculty of Medicine MU Investigator: Prof. MUDr. Roman Hájek, CSc.
Field:	FD - Oncology and hematology (F - Medicine)
Publications/Results:	more
Keywords:	multiple myeloma; proteomics; genomics

Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. In the last decade, there have been dramatic developments in basic and applied research in the field. New treatments have become available and treatment standards have changed. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. However, the disease is still incurable. The treatment strategy today includes potentially 3-5 regimens administered over a period of 10 to 15 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate.